CRESCENT BIOPHARMA, INC. CBIO
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
3/9
Piotroski F — financial health
4.59
Altman Z″ — distress risk · safe
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $10.8M | -$153.9M | — | -$72.5M | $203.0M |
| 2024 | — | -$37.9M | — | -$31.1M | -$15.5M |
| 2023 | $10,000 | -$36.9M | — | -$34.9M | $38.4M |
| 2022 | $75,000 | -$46.7M | — | -$46.5M | $42.9M |
| 2021 | $1.2M | -$63.4M | — | -$57.5M | $81.6M |
| 2020 | $10.2M | -$51.0M | — | -$39.3M | $128.2M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 4.59 (safe)
- Working capital / assets 0.835
- Retained earnings / assets -0.715
- EBIT / assets -0.635
- Equity / liabilities 5.445
Source: SEC EDGAR filings · CIK 0001253689 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.